Congresswoman Jennifer Wexton (D-VA-10) introduced the bipartisan Gabriella Miller Kids First Research Act 2.0 (HR 6556) which would redirect penalties collected from pharmaceutical companies that break the law to critical rare pediatric disease research. Representatives Tom Cole (R-OK-04), Peter Welch (D-VT-At Large) and Gus Bilirakis (R-FL-12) joined Wexton in introducing the legislation.
Simple as 1,2, 3, More funding for Pediatric Cancer and Rare Disease Research
Here’s how the Gabriella Miller Kids First Act 2.0 will create more research for childhood cancer and rare pediatric diseases: Under the Food, Drug, and Cosmetic Act, related companies under this act that violate its laws must pay fines. Under the new Kids First 2.0 Act, the fines are collected and transferred to the National Institutes of Health (NIH), which funds the GMKF Pediatric Research Initiative Fund. The fund was started 6 years ago as a result of the original Gabriella Miller Kids First Research Act and so far has generated $75 million in research and data collection improvements and is expected to add $50 million more in the next 4 years. The new HR 6556 Gabriella Miller Kids First Act 2.0 is expected to generate much more funding. Please add you support as we all go forward to getting this exciting legislation passed. Here are the details: https://wp.me/p2TETU-1Va
Want to Help? See below:
If you have an organization that supports either childhood cancer or rare disease in any way, we need you to sign up today so that we may build our list of supporters. It’s very easy to do and will only take a minute or two. Your organization does not need to be a 501 3C organization to sign up for support of The Gabriella Miller Kids First Act 2.
Step Two: Thank the people who made this possible
Please take a moment and thank these four Congressional Representatives who stepped up in a bipartisan manner to help childhood cancer, and rare disease kids.
Download each graphic below to use in your Facebook posts and in Tweets: